Previous close | 0.8000 |
Open | 0.8000 |
Bid | 0.4500 |
Ask | 2.6000 |
Strike | 5.00 |
Expiry date | 2024-11-15 |
Day's range | 0.8000 - 0.8000 |
Contract range | N/A |
Volume | |
Open interest | 77 |
Key Insights Sutro Biopharma to hold its Annual General Meeting on 6th of June Total pay for CEO Bill Newell includes...
- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 - - Patient expansion phase well underway in Phase 2 study of luvelta in combination with bevacizumab; enrollment is expected to complete in the first half of 2024 - - The randomized portion of REFRαME-O1, the registration-enabling study of luvelta for patients with platinum-resistant ovarian cancer, is
Sutro Biopharma (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.